Preclinical data suggest that a PARP inhibitor in combination with carboplatin or cisplatin has enhanced efficacy over either agent individually in BRCA-mutated tumours (Evers et al, 2008; Drew et al, 2011; Clark et al, 2012). This evidence concerns the gene PARP1 and neoplasm.